Clinical Study of Cefiderocol (S-649266) for the Treatment of Nosocomial Pneumonia Caused by Gram-negative Pathogens (APEKS-NP)

A Multicenter, Randomized, Double-blind, Parallel-group, Clinical Study of S-649266 Compared With Meropenem for the Treatment of Hospital-acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia, or Healthcare-associated Bacterial Pneumonia Caused by Gram-negative Pathogens

The primary objective of this study is to compare all-cause mortality at Day 14 in participants receiving cefiderocol with participants receiving the comparator, meropenem, in adults with hospital-acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), or healthcare-associated bacterial pneumonia (HCABP) caused by Gram-negative pathogens.

Study Overview

• Status: Completed
• Conditions: Hospital Acquired Pneumonia (HAP); Healthcare-associated Pneumonia (HCAP); Ventilator Associated Pneumonia (VAP)
• Intervention / Treatment: Drug: Cefiderocol; Drug: Linezolid; Drug: Meropenem

• Study Type: Interventional
• Enrollment (Actual): 300
• Phase: Phase 3

Expanded Access

Approved for sale to the public. See expanded access record.

Contacts and Locations

Study Locations

• Belgium
  • Brussels, Belgium, 1020
    • Shionogi Research Site
  • Brussels, Belgium, 1070
    • Shionogi Research Site
• Canada
  • Nova Scotia
    • Halifax, Nova Scotia, Canada, B3H3A7
      • Shionogi Research Site
  • Ontario
    • Kingston, Ontario, Canada, K7L 2V7
      • Shionogi Research Site
• Czechia
  • Brno, Czechia, 65693
    • Shionogi Research Site
  • Hradec Kralove, Czechia, 50005
    • Shionogi Research Site
  • Kolin, Czechia, 28000
    • Shionogi Research Site
  • Kyjov, Czechia, 69701
    • Shionogi Research Site
  • Ostrava-Poruba, Czechia, 708 52
    • Shionogi Research Site
  • Prague, Czechia, 15006
    • Shionogi Research Site
  • Pribram, Czechia, 26101
    • Shionogi Research Site
• Estonia
  • Kohtla-Jarve, Estonia, 31025
    • Shionogi Research Site
  • Parnu, Estonia, 80010
    • Shionogi Research Site
  • Tallin, Estonia, 13419
    • Shionogi Research Site
  • Tartu, Estonia, 51014
    • Shionogi Research Site
• France
  • Angers, France, 49933
    • Shionogi Research Site
  • Argenteuil, France, 95100
    • Shionogi Research Site
  • Bron, France, 69677
    • Shionogi Research Site
  • LaRoche-sur-Yon, France, 85925
    • Shionogi Research Site
  • Lyon Cedex, France, 69437
    • Shionogi Research Site
  • Nice, France, 06202
    • Shionogi Research Site
  • Paris Cedex, France, 75018
    • Shionogi Research Site
• Georgia
  • Batumi, Georgia, 6010
    • Shionogi Research Site
  • Kutaisi, Georgia, 4600
    • Shionogi Research Site
  • Kutaisi, Georgia, 4601
    • Shionogi Research Site
  • Tbilisi, Georgia, 0160
    • Shionogi Research Site
• Germany
  • Bonn, Germany, 53127
    • Shionogi Research Site
  • Hamburg, Germany, 20246
    • Shionogi Research Site
  • Heidelberg, Germany, 69120
    • Shionogi Research Site
  • Leipzig, Germany, 04103
    • Shionogi Research Site
• Hungary
  • Budapest, Hungary, 1121
    • Shionogi Research Site
  • Budapest, Hungary, 1125
    • Shionogi Research Site
  • Debrecen, Hungary, H-4031
    • Shionogi Research Site
  • Fehergyarmat, Hungary, 4900
    • Shionogi Research Site
  • Szekesfehervar, Hungary, 8000
    • Shionogi Research Site
• Israel
  • Holon, Israel, 58100
    • Shionogi Research Site
  • Jerusalem, Israel, 9103102
    • Shionogi Research Site
  • Tel Aviv, Israel, 64239
    • Shionogi Research Site
  • Tel Hashomer, Israel, 52621
    • Shionogi Research Site
  • Tikva, Israel, 49100
    • Shionogi Research Site
• Japan
  • Kumamoto, Japan, 860-0008
    • Shionogi Research Site
  • Gunma
    • Maebashi, Gunma, Japan, 371-8511
      • Shionogi Research Site
  • Ibaraki
    • Tsuchiura, Ibaraki, Japan, 300-8585
      • Shionogi Research Site
  • Mie
    • Tsu-city, Mie, Japan, 514-8507
      • Shionogi Research Site
  • Okinawa
    • Shimajiri-gun, Okinawa, Japan, 901-1193
      • Shionogi Research Site
  • Tokyo
    • Itabashi-ku, Tokyo, Japan, 173-8610
      • Shionogi Research Site
• Latvia
  • Daugavpils, Latvia, LV-5417
    • Shionogi Research Site
  • Liepaja, Latvia, LV-3414
    • Shionogi Research Site
  • Riga, Latvia, LV-1006
    • Shionogi Research Site
  • Saldus Novads, Latvia, LV-1002
    • Shionogi Research Site
• Philippines
  • Caloocan City, Philippines, 1427
    • Shionogi Research Site
  • Iloilo City, Philippines, 5000
    • Shionogi Research Site
  • Manila, Philippines, 1000
    • Shionogi Research Site
  • Iloilo City
    • Jaro, Iloilo City, Philippines, 5000
      • Shionogi Research Site
  • Manila
    • Tondo, Manila, Philippines, 1012
      • Shionogi Research Site
  • Metro Manila
    • Caloocan, Metro Manila, Philippines, 1400
      • Shionogi Research Site
    • Quezon City, Metro Manila, Philippines, 1104
      • Shionogi Research Site
    • Quezon City, Metro Manila, Philippines, 1109
      • Shionogi Research Site
• Puerto Rico
  • San Juan, Puerto Rico, 00921
    • Shionogi Research Site
• Russian Federation
  • Barnaul, Russian Federation, 656024
    • Shionogi Research Site
  • Barnaul, Russian Federation, 656045
    • Shionogi Research Site
  • Chelyabinsk, Russian Federation, 454000
    • Shionogi Research Site
  • Krasnodar, Russian Federation, 350012
    • Shionogi Research Site
  • Moscow, Russian Federation, 105203
    • Shionogi Research Site
  • Moscow, Russian Federation, 115280
    • Shionogi Research Site
  • Moscow, Russian Federation, 127015
    • Shionogi Research Site
  • Novosibirsk, Russian Federation, 630051
    • Shionogi Research Site
  • Novosibirsk, Russian Federation, 630075
    • Shionogi Research Site
  • Sait-Petersburg, Russian Federation, 194354
    • Shionogi Research Site
  • Smolensk, Russian Federation, 214019
    • Shionogi Research Site
  • St. Petersburg, Russian Federation, 192242
    • Shionogi Research Site
  • St. Petersburg, Russian Federation, 196247
    • Shionogi Research Site
  • St. Petersburg, Russian Federation, 197706
    • Shionogi Research Site
  • St. Petersburg, Russian Federation, 454091
    • Shionogi Research Site
  • Tomsk, Russian Federation, 634063
    • Shionogi Research Site
• Serbia
  • Belgrade, Serbia, 11000
    • Shionogi Research Site
  • Kragujev Ac, Serbia, 34000
    • Shionogi Research Site
  • Sremska Kamenica, Serbia, 21204
    • Shionogi Research Site
• Spain
  • Alicante, Spain, 03010
    • Shionogi Research Site
  • Barcelona, Spain, 08003
    • Shionogi Research Site
  • Barcelona, Spain, 08026
    • Shionogi Research Site
  • Barcelona, Spain, 8036
    • Shionogi Research Site
  • Madrid, Spain, 28007
    • Shionogi Research Site
  • Madrid, Spain, 28922
    • Shionogi Research Site
  • Torrejon de Ardoz, Spain, 28850
    • Shionogi Research Site
  • Torrevieja, Spain, 03186
    • Shionogi Research Site
  • Valencia, Spain, 46010
    • Shionogi Research Site
• Taiwan
  • New Taipei City, Taiwan, 235
    • Shionogi Research Site
  • Taichung, Taiwan, 40705
    • Shionogi Research Site
  • Taipei, Taiwan, 10002
    • Shionogi Research Site
  • Taipei, Taiwan, 11696
    • Shionogi Research Site
• Ukraine
  • Chernivtsi, Ukraine, 58001
    • Shionogi Research Site
  • Dnipropetrovsk, Ukraine, 49000
    • Shionogi Research Site
  • Ivano Frankivsk, Ukraine, 76008
    • Shionogi Research Site
  • Kharkiv, Ukraine, 61037
    • Shionogi Research Site
  • Kharkiv, Ukraine, 61103
    • Shionogi Research Site
  • Kherson, Ukraine, 73000
    • Shionogi Research Site
  • Kiev, Ukraine, 01133
    • Shionogi Research Site
  • Kiev, Ukraine, 041112
    • Shionogi Research Site
  • Kremenchuk, Ukraine, 39617
    • Shionogi Research Site
  • Poltava, Ukraine, 36038
    • Shionogi Research Site
  • Sumy, Ukraine, 40031
    • Shionogi Research Site
  • Vinnitsya, Ukraine, 21029
    • Shionogi Research Site
  • Zaporizhzhya, Ukraine, 69035
    • Shionogi Research Site
• United States
  • Connecticut
    • New Haven, Connecticut, United States, 06511
      • Shionogi Research Site
  • Florida
    • DeLand, Florida, United States, 32720
      • Shionogi Research Site
  • Illinois
    • Chicago, Illinois, United States, 60612
      • Shionogi Research Site
  • Iowa
    • Council Bluffs, Iowa, United States, 51503
      • Shionogi Research Site
  • Kentucky
    • Louisville, Kentucky, United States, 40202
      • Shionogi Research Site
  • Louisiana
    • Baton Rouge, Louisiana, United States, 70808
      • Shionogi Research Site
    • Shreveport, Louisiana, United States, 71103
      • Shionogi Research Site
  • Maryland
    • Annapolis, Maryland, United States, 21404
      • Shionogi Research Site
  • Michigan
    • Detroit, Michigan, United States, 48201
      • Shionogi Research Site
  • Missouri
    • Saint Louis, Missouri, United States, 63110-0250
      • Shionogi Research Site
  • Ohio
    • Cleveland, Ohio, United States, 44106
      • Shionogi Research Site
    • Columbus, Ohio, United States, 43210-1267
      • Shionogi Research Site
  • Pennsylvania
    • Bethlehem, Pennsylvania, United States, 18105
      • Shionogi Research Site
    • Philadelphia, Pennsylvania, United States, 19141
      • Shionogi Research Site
  • Utah
    • Salt Lake City, Utah, United States, 84132
      • Shionogi Research Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Subjects 18 years or older at the time of signing informed consent
• Subjects who have provided written informed consent or their informed consent has been provided by a legally authorized representative
• Subjects who meet the clinical diagnosis criteria for hospital-acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), or healthcare-associated bacterial pneumonia (HCABP)

• All subjects must fulfill at least 1 of the following clinical criteria at screening:

  1. New onset or worsening of pulmonary symptoms or signs, such as cough, dyspnea, tachypnea (eg, respiratory rate > 25 breaths/minute), expectorated sputum production, or requirement for mechanical ventilation
  2. Hypoxemia (eg, a partial pressure of oxygen [PaO2] < 60 mm Hg while the subject is breathing room air, as determined by arterial blood gas [ABG], or worsening of the ratio of the PaO2 to the fraction of inspired oxygen [PaO2/FiO2])
  3. Need for acute changes in the ventilator support system to enhance oxygenation, as determined by worsening oxygenation (ABG or PaO2/FiO2) or needed changes in the amount of positive end-expiratory pressure
  4. New onset of or increase in (quantity or characteristics) suctioned respiratory secretions, demonstrating evidence of inflammation and absence of contamination

• All subjects must have at least 1 of the following signs:

  1. Documented fever (ie, core body temperature [tympanic, rectal, esophageal] ≥ 38°C [100.4°F], oral temperature ≥ 37.5°C, or axillary temperature ≥ 37°C)
  2. Hypothermia (ie, core body temperature [tympanic, rectal, esophageal] ≤ 35°C [95.0°F], oral temperature ≤ 35.5°C and axillary temperature ≤ 36°C)
  3. Leukocytosis with a total peripheral white blood cell (WBC) count ≥ 10,000 cells/mm³
  4. Leukopenia with total peripheral WBC count ≤ 4500 cells/mm³
  5. Greater than 15% immature neutrophils (bands) noted on peripheral blood smear
• All subjects must have a chest radiograph during screening showing the presence of new or progressive infiltrate(s) suggestive of bacterial pneumonia. A computed tomography (CT) scan in the same time window showing the same findings could also be acceptable
• All subjects must have a suspected Gram-negative infection involving the lower respiratory tract

Exclusion Criteria:

• Subjects who have known or suspected community-acquired bacterial pneumonia (CABP), atypical pneumonia, viral pneumonia, or chemical pneumonia (including aspiration of gastric contents, inhalation injury)
• Other exclusions based on the prescribing information of meropenem or linezolid, prior antibiotic usage, age, and pregnancy.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: TRIPLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Cefiderocol; Participants will receive 2 g cefiderocol administered intravenously every 8 hours for 7 to 14 days and 600 mg linezolid administered intravenously every 12 hours for at least 5 days.	Drug: Cefiderocol; 2000 mg intravenously every 8 hours for a period of 7 to14 days (dosage adjustment is necessary based on renal function); Other Names: S-649266; Drug: Linezolid; 600 mg of linezolid administered intravenously over 30 minutes to 2 hours, every 12 hours.; Other Names: Zyvox®
ACTIVE_COMPARATOR: Meropenem; Participants will receive 2 g meropenem administered intravenously every 8 hours for 7 to 14 days and 600 mg linezolid administered intravenously every 12 hours for at least 5 days.	Drug: Linezolid; 600 mg of linezolid administered intravenously over 30 minutes to 2 hours, every 12 hours.; Other Names: Zyvox®; Drug: Meropenem; 2000 mg intravenously every 8 hours for a period of 7 to 14 days (dosage adjustment is necessary based on renal function); Other Names: Merrem®

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
All-cause Mortality Rate at Day 14	The all-cause mortality (ACM) rate at Day 14 was calculated as the percentage of participants in each treatment group who experienced mortality, regardless of the cause, from the first infusion of study drug up to Day 14. The Modified Intent-to-Treat Population included all randomized participants who met either of the following criteria: Evidence of Gram-negative infection of the lower respiratory tract based on a culture, Gram-stain, or other diagnostic test; Evidence of a lower respiratory tract infection but culture or other diagnostic tests did not provide a microbiologic diagnosis	From first dose of study drug to Day 14

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants With Microbiologic Eradication at Test of Cure (TOC)	Lower respiratory tract specimens (eg, sputum, endotracheal aspiration [ETA], endobronchial culture specimens collected by bronchoalveolar lavage [BAL], or protected specimen brush [PSB], lung biopsy tissue, pleural effusions, etc) were sent to the local microbiology laboratory for isolation and identification of pathogens. Microbiological outcome by Baseline pathogen at TOC was determined by the sponsor as either Eradication, Persistence, or Indeterminate. Overall per-participant microbiological outcome was determined based on the individual microbiological outcomes for each Baseline pathogen. Eradication: Absence of all Baseline Gram-negative pathogens from an appropriate clinical specimen (sputum, tracheal aspirate, bronchoalveolar lavage (BAL) fluid, protected specimen brush, pleural fluid, or lung biopsy). If it was not possible to obtain an appropriate clinical culture, and the participant had a successful clinical outcome, the response was presumed as eradication.	Test of cure (7 days after end of treatment; equivalent to Study Day 14 to 21)
Percentage of Participants With Clinical Cure at Test of Cure	Clinical outcome was assessed by the investigator as either Clinical Cure, Clinical Failure, or Indeterminate. Clinical Cure: Resolution or substantial improvement of Baseline signs and symptoms of pneumonia, including a reduction in Sequential Organ Failure Assessment (SOFA) and Clinical Pulmonary Infection Score (CPIS) scores, and improvement or lack of progression of chest radiographic abnormalities such that no additional antibacterial therapy was required for the treatment of the current infection.	Test of cure (7 days after the end of treatment; equivalent to Study Day 14 to 21)
Percentage of Participants With Clinical Cure at Early Assessment (EA)	Clinical outcome was assessed by the investigator as either Clinical Cure, Clinical Failure, or Indeterminate. Clinical Cure: Resolution or substantial improvement of Baseline signs and symptoms of pneumonia, including a reduction in Sequential Organ Failure Assessment (SOFA) and Clinical Pulmonary Infection Score (CPIS) scores, and improvement or lack of progression of chest radiographic abnormalities such that no additional antibacterial therapy was required for the treatment of the current infection.	Early assessment (Day 3-4 after the start of treatment)
Percentage of Participants With Clinical Cure at End of Treatment (EOT)	Clinical outcome was assessed by the investigator as either Clinical Cure, Clinical Failure, or Indeterminate. Clinical Cure: Resolution or substantial improvement of Baseline signs and symptoms of pneumonia, including a reduction in Sequential Organ Failure Assessment (SOFA) and Clinical Pulmonary Infection Score (CPIS) scores, and improvement or lack of progression of chest radiographic abnormalities such that no additional antibacterial therapy was required for the treatment of the current infection.	End of treatment (Day 7 to 14)
Percentage of Participants With Sustained Clinical Cure at Follow-up (FU)	Clinical outcome was assessed by the investigator at follow-up as either Sustained Clinical Cure, Relapse, or Indeterminate. Sustained Clinical Cure: Continued resolution or substantial improvement of Baseline signs and symptoms of pneumonia, such that no antibacterial therapy was required for the treatment of pneumonia in a participant assessed as cured at TOC.	Follow-up (14 days after the end of treatment; Day 21 to 28)
Percentage of Participants With Microbiologic Eradication at Early Assessment	Microbiological outcome by Baseline pathogen at Early Assessment was determined by the sponsor as either Eradication, Persistence, or Indeterminate. Overall per-participant microbiological outcome was determined based on the individual microbiological outcomes for each Baseline pathogen. Eradication: Absence of all Baseline Gram-negative pathogens from an appropriate clinical specimen (sputum, tracheal aspirate, BAL fluid, protected specimen brush, pleural fluid, or lung biopsy). If it was not possible to obtain an appropriate clinical culture, and the participant had a successful clinical outcome, the response was presumed as eradication.	Early Assessment, Days 3 to 4
Percentage of Participants With Microbiologic Eradication at End of Treatment	Microbiological outcome by Baseline pathogen at End of Treatment was determined by the sponsor as either: Eradication, Persistence, or Indeterminate. Overall per-participant microbiological outcome was determined based on the individual microbiological outcomes for each Baseline pathogen. Eradication: Absence of all Baseline Gram-negative pathogens from an appropriate clinical specimen (sputum, tracheal aspirate, BAL fluid, protected specimen brush, pleural fluid, or lung biopsy). If it was not possible to obtain an appropriate clinical culture, and the participant had a successful clinical outcome, the response was presumed as eradication.	End of treatment, Day 7 to 14
Percentage of Participants With Sustained Microbiologic Eradication at Follow-up	Microbiological outcome by Baseline pathogen at Follow-up was determined by the sponsor as either Sustained Eradication, Persistence, Recurrence, or Indeterminate. Overall per-participant microbiological outcome was determined based on the individual microbiological outcomes for each Baseline pathogen. Sustained eradication: Absence of all Baseline Gram-negative pathogens from an appropriate clinical specimen (sputum, tracheal aspirate, BAL fluid, protected specimen brush, pleural fluid, or lung biopsy) after TOC. If it was not possible to obtain an appropriate clinical culture and the participant had a successful clinical response after TOC, the response was presumed to be eradication.	Follow-up (14 days after the end of treatment, Days 21 to 28)
All-cause Mortality Rate at Day 28	The all-cause mortality (ACM) rate at Day 28 was calculated as the percentage of participants who experienced mortality, regardless of the cause, from the first dose of study drug up to Day 28.	From first dose of study drug to Day 28
All-cause Mortality Rate at the End of Study	The all-cause mortality rate during both the treatment and follow-up period (up to the end of study [EOS] visit) was calculated as the percentage of participants who experienced mortality, regardless of the cause, from the first infusion of study drug up to EOS. If a participant discontinued from the study before EOS and survival information was not available, then the survival status for this endpoint for the participant was considered unknown.	From first dose of study drug through end of study (28 days after end of treatment, up to 42 days)
Total Hospitalization Time	The length of hospital stay attributable to the study-qualifying infection.	From first dose of study drug to test of cure (7 days after end of treatment; equivalent to Study Day 14 to 21) and to follow-up (14 days after the end of treatment; Day 21 to 28)
Number of Participants With Treatment-Emergent Adverse Events	The severity of each adverse event (AE) was graded by the investigator according to the following definitions: Mild: A finding or symptom is minor and does not interfere with usual daily activities.; Moderate: The event causes discomfort and interferes with usual daily activity or affects clinical status.; Severe: The event causes an interruption of the participant's usual daily activities or has a clinically significant effect. The relationship of each AE to the study treatment was determined by the investigator based on whether the AE could be reasonably explained as having been caused by the study drug (treatment related AE [TRAE]). An SAE is defined as any AE occurring at any dose that resulted in any of the following outcomes: Death; Life-threatening condition; Hospitalization or prolongation of existing hospitalization for treatment; Persistent or significant disability/incapacity; Congenital anomaly/birth defect; Other medically important condition	From first dose of study drug through the end of study, up to 42 days.

Collaborators and Investigators

• Sponsor: Shionogi

Publications and helpful links

General Publications

• Nordmann P, Shields RK, Doi Y, Takemura M, Echols R, Matsunaga Y, Yamano Y. Mechanisms of Reduced Susceptibility to Cefiderocol Among Isolates from the CREDIBLE-CR and APEKS-NP Clinical Trials. Microb Drug Resist. 2022 Apr;28(4):398-407. doi: 10.1089/mdr.2021.0180. Epub 2022 Jan 24.
• Skaar EP, Echols R, Matsunaga Y, Menon A, Portsmouth S. Iron serum levels and iron homeostasis parameters in patients with nosocomial pneumonia treated with cefiderocol: post hoc analysis of the APEKS-NP study. Eur J Clin Microbiol Infect Dis. 2022 Mar;41(3):467-476. doi: 10.1007/s10096-021-04399-9. Epub 2022 Jan 13.
• Wenzler E, Butler D, Tan X, Katsube T, Wajima T. Pharmacokinetics, Pharmacodynamics, and Dose Optimization of Cefiderocol during Continuous Renal Replacement Therapy. Clin Pharmacokinet. 2022 Apr;61(4):539-552. doi: 10.1007/s40262-021-01086-y. Epub 2021 Nov 18. Erratum In: Clin Pharmacokinet. 2022 Jul;61(7):1069.
• Wunderink RG, Matsunaga Y, Ariyasu M, Clevenbergh P, Echols R, Kaye KS, Kollef M, Menon A, Pogue JM, Shorr AF, Timsit JF, Zeitlinger M, Nagata TD. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2021 Feb;21(2):213-225. doi: 10.1016/S1473-3099(20)30731-3. Epub 2020 Oct 12.

Study record dates

Study Major Dates

• Study Start (ACTUAL): October 24, 2017
• Primary Completion (ACTUAL): February 26, 2019
• Study Completion (ACTUAL): April 1, 2019

Study Registration Dates

• First Submitted: January 17, 2017
• First Submitted That Met QC Criteria: January 23, 2017
• First Posted (ESTIMATE): January 26, 2017

Study Record Updates

• Last Update Posted (ACTUAL): November 13, 2020
• Last Update Submitted That Met QC Criteria: October 20, 2020
• Last Verified: October 1, 2020

More Information

Terms related to this study

• Keywords: meropenem; pneumonia; S-649266; cefiderocol; linezolid; nosocomial pneumonia; Gram-negative pathogens; Healthcare-associated pneumonia (HCAP); Ventilator-associated pneumonia (VAP); Hospital-acquired pneumonia (HAP)
• Additional Relevant MeSH Terms: Pathologic Processes; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Lung Diseases; Disease Attributes; Cross Infection; Iatrogenic Disease; Healthcare-Associated Pneumonia; Pneumonia; Pneumonia, Ventilator-Associated; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Enzyme Inhibitors; Anti-Bacterial Agents; Protein Synthesis Inhibitors; Linezolid; Meropenem
• Other Study ID Numbers: 1615R2132; 2016-003020-23 (EUDRACT_NUMBER)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No